SLC5A2 and cancer: However, an overall null effect of SGLT2 inhibitor on NOS was seen for participants with cancer, chronic obstructive pulmonary disease, and rheumatic arthritis, and concurrent medication with a nonsteroidal anti-inflammatory drug, H2 receptor antagonist, an alpha-glucosidase inhibitor, and dipeptidyl peptidase 4 inhibitor (Table 3).